Company intelligence / Profile preview

Coeptis Pharmaceuticals

Pittsburgh, Pennsylvania, United States

Ownership: Public · ZSQR
Development stage: Other

Overview

DVX-201 (unmodified NK cells) in Phase 1 for relapsed/refractory AML/high-risk MDS (enrolling, no DLTs at dose level 900M, LPLV expected 2Q24); completed Phase 1 for acute viral respiratory diseases. Preclinical programs in SNAP-CAR NK/T and CD38-GEAR-NK.

Therapeutic areas: OncologyInfectious DiseasesHematologyImmunology
Modalities: Cell therapyNatural killer cell therapyCAR-T cell therapyGene-edited cell therapy
Industry: Biotech

Drug pipeline

8 assets

eltoprazine

7 more assets in the full pipeline.

Request access →

Partnerships

Deverra TherapeuticsUniversity of PittsburghVyGen-BioFred Hutch Cancer CenterDuke Cancer InstituteNovant Health

Financials

Market cap: $19.2M
Total revenue: $1.6M
Enterprise value: $3.7M

Beyond the preview

Go deeper on Coeptis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coeptis Pharmaceuticals.

Explore the full profile